Pfizer, BioNTech Positive Topline Data for mRNA-based Combo Influenza and COVID-19 Vax

 

• Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains
• Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’ COVID-19 vaccine
• The companies plan to start a pivotal Phase 3 trial in the coming months

https://www.biospace.com/article/releases/pfizer-and-biontech-announce-positive-topline-data-for-mrna-based-combination-vaccine-program-against-influenza-and-covid-19/